Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selinexor + dexamethasone
- Development stage
- Phase 3
- Lead developer
- Karyopharm Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Selinexor + dexamethasone is a combination therapy used to treat multiple myeloma. Selinexor is a selective inhibitor of nuclear export (SINE) that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA translation. This combination is primarily used in patients with relapsed or refractory multiple myeloma who have received multiple prior therapies.
- Brand names
- XPOVIO + dexamethasoneNEXPOVIO + dexamethasone
- Other names
- Sd
02
Targets
XPO1 (Exportin-1)GR (Glucocorticoid receptor)NF-κB
Beyond the preview
Go deeper on selinexor + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selinexor + dexamethasone.